These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36531703)

  • 1. Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis.
    Chen X; Wang L; Li H; Huang W; Huang S; Zhao L; Guo W
    Front Cardiovasc Med; 2022; 9():1067806. PubMed ID: 36531703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis.
    Chen C; Peng H; Li M; Lu X; Huang M; Zeng Y; Dong G
    Front Endocrinol (Lausanne); 2021; 12():664533. PubMed ID: 34759887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
    Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
    Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
    Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B; Ghosal S
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
    Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
    J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis.
    Zhao L; Guo W; Huang W; Wang L; Huang S
    Diabetes Res Clin Pract; 2022 May; 187():109871. PubMed ID: 35413392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis.
    Glover S; Borrego ME; Ray GM; Roberts MH
    Clinicoecon Outcomes Res; 2022; 14():465-477. PubMed ID: 35845354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
    Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
    Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    Lingyan Z; Zijia H; Ya Z; Ying Z
    J Cardiovasc Pharmacol; 2024 Jul; ():. PubMed ID: 39027979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
    Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.